Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00795275 · ClinicalTrials.gov registry record · NA
Incretin Effect in People With Impaired Fasting Glucose
A NA study, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- NA
- Development phase
- 26
- Enrollment target
NCT00795275 is a NA study that has completed, run by University of Colorado, Denver. The registered enrollment target is 26 participants.
The verdict
NCT00795275, a NA study, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- NA
- Development phase
- 26 participants
- Enrollment target
Study Summary
Regulation of endogenous glucose production (EGP) and insulin secretion are major actions of glucagon-like peptide-1 (GLP-1). Determining whether alterations in GLP-1 may contribute to abnormal EGP and insulin secretion in people with impaired fasting glucose (IFG) was the objective of the current study. The investigators hypothesized that defects in GLP-1 may explain the inappropriate basal EGP and diminished insulin secretion in IFG, and, furthermore, that by increasing circulating GLP-1 levels (using a new medicine called "sitagliptin") the investigators could reverse these defects.
Interventions
- DRUG Sitagliptin Phosphate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2008-01 |
| Est. Completion | 2008-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00795275
The ClinicalTrials.gov registry entry for NCT00795275 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sitagliptin Phosphate is the first listed.
NCT00795275 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00795275 about?
NCT00795275 is a clinical study titled "Incretin Effect in People With Impaired Fasting Glucose". Regulation of endogenous glucose production (EGP) and insulin secretion are major actions of glucagon-like peptide-1 (GLP-1). Determining whether alterations in GLP-1 may contribute to abnormal EGP and insulin secretion in people with impaired fasting glucose (IFG) was the objective of the current s...
What is the current status of trial NCT00795275?
This trial is currently completed. It is a NA study. The enrollment target is 26 participants. The study started on 2008-01. Estimated completion is 2008-11.
What interventions are being tested in trial NCT00795275?
The interventions under investigation include: Sitagliptin Phosphate (DRUG).
Who is sponsoring clinical trial NCT00795275?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.